"Favipiravir has already demonstrated positive outcomes on Covid-19 patients"- Dr R Ananthanarayanan
30 April 2020 | Views
Dr R Ananthanarayanan, CEO and Managing Director, - Strides Pharma Science talks about the company's contribution in the fight against COVID-19
“We are pleased to be the First Indian Company to develop and commercially launch Favipiravir tablets for the global markets. This development reinforces our commitment to play a substantial role in society by bringing affordable and quality healthcare to millions of people around the globe. Favipiravir has already demonstrated positive outcomes in several studies on Covid-19 patients, and we are hopeful that the treatment regime with Favipiravir would brace up our fight against this virus. Favipiravir is a complex drug to make, while we are manufacturing the tablets in-house, we are also excited to partner with the API manufacturer such that our supply chain remains secured up to the key starting material.”
Dr R Ananthanarayanan, CEO and Managing Director, Strides Pharma Science
